Clinical trial · Observational
Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.
NCT06326086CI-TRIAL-00075309unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is a common disease leading to 18 % of cancer deaths worldwide. Despite various improvement in treatment, there still remains low 5-year survival rate of 10-20 % in advanced lung cancer patients. Skeletal muscle mass and physical performance have been shown to effect overall survival and prognosis in lung cancer. This research focuses on effects of different treatment of lung cancer such as chemotherapy, targeted therapy and immunotherapy on skeletal muscle mass and physical performance.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy drug | Drug | — | UNRESOLVED |
| Immunotherapy | Drug | Immunotherapy | ALIAS |
| Targeted Agent | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CMT for patients receiving chemotherapy,
- interventionNames
- Drug: Chemotherapy drug
- label
- TKI/IO for patients receiving targeted and immunotherapy
- interventionNames
- Drug: Targeted Agent
- Drug: Immunotherapy
Primary outcomes (1)
- measure
- To determine the differences in the rate of decline in CT defined skeletal muscle index at L3 vertebra and physical performance in advanced NSCLC patients receiving chemotherapy and targeted therapy/ immunotherapy, before and after treatment.
- timeFrame
- 1 year
- description
- To determine the differences in the rate of decline in CT defined skeletal muscle index at L3 vertebra and physical performance in advanced NSCLC patients receiving chemotherapy and targeted therapy/ immunotherapy, before and after treatment.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \>18years old, 2. Stage IIIB and IIIC (if patients are treated with TKI/IO), and Stage IV non-small cell lung cancer patients confirmed by histopathology. 3. Patients should be either on chemotherapy, molecular targeted therapy or immunotherapy. Exclusion Criteria: 1. Unable to perform CT scan due to various reasons. 2. Patients with metastatic disease at L3 vertebral level. 3. If unable to perform SPPB test due to physical disability or patient's refusal. 4. Patients with known other primary malignancies. 5 . Patients who have underwent definitive surgery. 6\. Pregnant patients. 7. Patients with physical deformities/neurological deficits which restricts their physical movements.
References
Publications (0)
Data not yet available
No reference posted for this study.